Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Thursday 5 May 2016

Venue: 10 Spring Gardens
London
SW1A 2BU

Present:
1. Dr Amanda Adler (Chair) Present for all notes
2. Dr Sanjeev Patel (Vice-Chair) Present for all notes
3. Professor John Cairns Present for all notes
4. Mr Mark Chapman Present for all notes
5. Dr Mark Glover Present for all notes
6. Dr Neil losson Present for all notes
7. Dr Sanjay Kinra Present for all notes
8. Dr Miriam McCarthy Present for all notes
9. Professor Ruairidh Milne Present for all notes
10. Mr Christopher O'Regan Present for all notes
11. Professor John Pounsford Present for all notes
12. Dr Danielle Preedy Present for all notes
13. Mr Alun Roebuck Present for all notes
14. Dr Nigel De-Kare Silver Present for all notes
15. Dr Marta Soares Present for notes 1 to 17 and notes 29 to 40
16. Dr Nicky Welton Present for all notes
17. Mr Nigel Westwood Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Dr Melinda Goodall Associate Director, National Institute for Health and Care Excellence Present for all notes

Jeremy Powell Project Manager, National Institute for Health and Care Excellence Present for all notes

Marcia Miller Administrator, National Institute for Health and Care Excellence Present for all notes
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Presence Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sophie Laurenson</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 1 to 17</td>
</tr>
<tr>
<td>Dr Rosie Lovett</td>
<td>Technical Adviser, National Institute for Health and Clinical Excellence</td>
<td>Present for notes 1 to 17</td>
</tr>
<tr>
<td>Jasdeep Hayre</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 18 to 28</td>
</tr>
<tr>
<td>Raisa Sidhu</td>
<td>Technical Adviser, National Institute for Health and Clinical Excellence</td>
<td>Present for notes 18 to 40</td>
</tr>
<tr>
<td>Helen Tucker</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 29 to 40</td>
</tr>
<tr>
<td>Ms Sarah Davis</td>
<td>Senior Lecturer in Health Economics, School of Health and Related Research, University of Sheffield</td>
<td>Present for notes 1 to 15</td>
</tr>
<tr>
<td>Mr Rachid Rafia</td>
<td>Research Fellow, School of Health and Related Research, University of Sheffield</td>
<td>Present for notes 1 to 15</td>
</tr>
<tr>
<td>Dr Jean Sanderson</td>
<td>Research Associate, School of Health and Related Research, University of Sheffield</td>
<td>Present for notes 1 to 15</td>
</tr>
<tr>
<td>Dr Toby Maher</td>
<td>Consultant Respiratory Physician, Royal Brompton Hospital, clinical expert, nominated by Roche</td>
<td>Present for notes 5 to 13</td>
</tr>
<tr>
<td>Professor Anna Murphy</td>
<td>Consultant Respiratory Pharmacist, University Hospitals of Leicester NHS Trust, clinical expert, nominated by NHS England</td>
<td>Present for notes 5 to 13</td>
</tr>
<tr>
<td>Mr Ronald Flewett</td>
<td>Patient expert, nominated by the Pulmonary Fibrosis Trust</td>
<td>Present for notes 5 to 13</td>
</tr>
<tr>
<td>Mr Malcolm Weallans</td>
<td>Treasurer of Pulmonary Fibrosis Trust, patient expert, nominated by the</td>
<td>Present for notes 5 to 13</td>
</tr>
</tbody>
</table>
Ms Kathy Blacker  Pulmonary Fibrosis Trust
Regional POC Manager - Accountable
Commissioner for Specialised Respiratory CRG, Commissioning expert, nominated by NHS England
Present for notes 5 to 13

Dr Nerys Woolacott  Senior Research Fellow, Centre for Reviews and Dissemination, University of York
Present for notes 18 to 26

Mr Rob Hodgson  Health Economist, Centre for Reviews and Dissemination, University of York
Present for notes 18 to 26

Mr Mousumi Biswas  Research Fellow in Health Economics, Centre for Reviews and Dissemination, University of York
Present for notes 18 to 26

Dr Martin Forster  Clinical Senior Lecturer and Honorary Medical Oncologist, clinical expert, nominated by Pfizer
Present for notes 18 to 26

Professor Andrew Nicholson  Consultant Pathologist & Professor of Respiratory Pathology, clinical expert, nominated by the Royal College of Pathologists
Present for notes 18 to 26

Mrs Carol Davies  Macmillan lung cancer nurse specialist, patient expert, nominated by the National Lung Cancer Forum for Nurses
Present for notes 18 to 26

Dr Jesme Fox  Medical Director, Roy Castle Lung Cancer Foundation, patient expert, nominated by the Roy Castle Lung Cancer Foundation
Present for notes 18 to 26

Professor Matt Stevenson  Technical Director, School of Health and Related Research, University of Sheffield
Present for notes 29 to 37

Dr Inigo Bermejo  Research Associate, School of Health and Related Research, University of Sheffield
Present for notes 29 to 37

Dr Katy Cooper  Senior Research Associate, School of Health and Related
Present for notes 29 to 37
Research, University of Sheffield

Non-public observers:

Helen Barnett  Medical Editor, NICE  Present for all notes
Chloe Kastoryano  Public Involvement Adviser, Patient Involvement Programme, NICE  Present for notes 1 to 28
Heidi Livingstone  Senior Public Involvement Advisor, Patient Involvement Programme, NICE  Present for notes 1 to 28
Edgar Masanga  Business Analyst - Resource Impact Assessment, NICE  Present for notes 1 to 28
Jennifer Dickson  Scottish Medicines Consortium  Present for notes 1 to 28
Lindsay Lockart  Scottish Medicines Consortium  Present for notes 1 to 28
Phil Morgan  Health Economist, Centre for Reviews and Dissemination, University of York  Present for notes 1 to 28

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282) [ID837], crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer [ID865] and mepolizumab for treating severe eosinophilic asthma [ID798].

2. The Chair informed the Committee of the non-public observers at this meeting: Helen Barnett, Chloe Kastoryano, Heidi Livingstone, Edgar Masanga, Jennifer Dickson, Lindsay Lockart and Phil Morgan.

3. Apologies were received from Dr Ray Armstrong, Dr Jeff Aronson, Anne Joshua, Dr Rebecca Kearney, Professor Stephen Palmer and Professor Ken Stein.

Any other Business

4. The Committee were given an update on the progress of other appraisals.

Appraisal of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282) [ID837]

Part 1 – Open session
5. The Chair welcomed the invited experts: Ms Sarah Davis, Mr Rachid Rafia, Dr Jean Sanderson, Dr Toby Maher, Professor Anna Murphy, Mr Ronald Flewett, Mr Malcolm Weallans and Ms Kathy Blacker to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Roche to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Dr Amanda Adler, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Neil Iosson, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Mr Christopher O'Regan, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Mr Alun Roebuck, Dr Nigel De-Kare Silver, Dr Marta Soares, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282).

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282).

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

9.1. Ms Sarah Davis, Mr Rachid Rafia, Dr Jean Sanderson, Mr Ronald Flewett, Mr Malcolm Weallans and Ms Kathy Blacker declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282).

9.2. Dr Toby Maher declared a personal specific financial interest as he has received consultancy and speaker fees from Roche and Boehringer Ingelheim.

9.2.1. It was agreed that this declaration would not prevent Dr Maher from participating in this section of the meeting

9.3. Professor Anna Murphy declared a personal specific financial interest as she has received speaker fees and attended advisory boards for Roche and Boehringer Ingelheim.

9.3.1. It was agreed that this declaration would not prevent Professor Murphy from participating in this section of the meeting
10. The Chair introduced the lead team, Dr Sanjay Kinra, Mr Mark Chapman and Mr Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of Dr Sanjay Kinra, Mr Mark Chapman and Mr Nigel Westwood.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued.

15. The Evidence Review Group representatives left the meeting.

16. The Committee continued to discuss the clinical and cost effectiveness of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282).

16.1. The committee decision was based on consensus.

17. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer [ID865]

Part 1 – Open session

18. The Chair welcomed the invited experts: Dr Nerys Woolacott, Mr Rob Hodgson, Mr Mousumi Biswas, Dr Martin Forster, Professor Andrew Nicholson, Mrs Carol Davies and Dr Jesme Fox to the meeting and they introduced themselves to the Committee.

19. The Chair welcomed company representatives from Pfizer to the meeting.

20. The Chair asked all Committee members to declare any relevant interests

20.1. Dr Amanda Adler, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Neil Ioossen, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruaidhrí Milne, Mr Christopher O'Regan, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Mr Alun Roebuck, Dr Nigel De-Kare Silver, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be
considered as part of the appraisal of crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer.

20.2. Dr Marta Soares declared a personal specific financial interest before the meeting as a family member is preparing a submission for Pfizer Portugal on crizotinib in this indication.  
9.2.1 It was agreed that this declaration would prevent Dr Soares from participating in this section of the meeting.

21. The Chair asked all NICE Staff to declare any relevant interests.

21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer.

22. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

22.1. Dr Nerys Woolacott, Mr Rob Hodgson, Mr Mousumi Biswas and Mrs Carol Davies and declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer.

22.2. Dr Martin Forster declared a personal specific financial interest as he is involved in educational and advisory roles for Pfizer, Novartis and Roche and is also involved in several studies with anaplastic lymphoma kinase targeted therapies.  
22.2.1 It was agreed that this declaration would not prevent Dr Forster from participating in this section of the meeting

22.3. Professor Andrew Nicholson declared a personal specific financial interest as he has attended educational and advisory boards for Novartis, Pfizer, AstraZeneca, Roche, Bristol Myers Suibb, Merck and Eli Lilly.  
22.3.1 It was agreed that this declaration would not prevent Professor Nicholson from participating in this section of the meeting

22.4. Dr Jesme Fox declared a personal non specific financial interest as as her employer, The Roy Castle Lung Cancer Foundation (RCLCF) has received grants from multiple pharmaceutical and commercial businesses for specific projects. She has also presented at many conferences and participated in several advisory boards, organised by multiple pharmaceutical companies. The honariria were given to the RCLCF.  
22.4.1 It was agreed that this declaration would not prevent Dr Fox from participating in this section of the meeting

23. The Chair introduced the lead team, Dr Miriam McCarthy, Professor John Cairns and Dr Dani Preedy who gave presentations on the clinical effectiveness and cost
effectiveness of crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer.

24. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

25. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

26. The Chair then thanked the experts, Evidence Review Group representatives and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

27. The Committee continued to discuss the clinical and cost effectiveness of crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer.

27.1. The committee decision was based on consensus.

28. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of mepolizumab for treating severe eosinophilic asthma [ID798]

Part 1 – Open session

29. The Chair welcomed the invited experts: Professor Matt Stevenson, Dr Inigo Bermejo and Dr Katy Cooper to the meeting and they introduced themselves to the Committee.

30. The Chair welcomed company representatives from GlaxoSmithKline to the meeting.

31. The Chair asked all Committee members to declare any relevant interests

31.1. Dr Amanda Adler, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Neil Iosson, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Mr Christopher O'Regan, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Mr Alun Roebuck, Dr Nigel De-Kare Silver, Dr Marta Soares, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of mepolizumab for treating severe eosinophilic asthma.

32. The Chair asked all NICE Staff to declare any relevant interests.

32.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest.
interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of mepolizumab for treating severe eosinophilic asthma.

33. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

33.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of mepolizumab for treating severe eosinophilic asthma.

34. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

35. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

36. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

37. The Chair then thanked the experts, Evidence Review Group representatives and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

38. The Committee continued to discuss the clinical and cost effectiveness of mepolizumab for treating severe eosinophilic asthma.

38.1. The committee decision was based on consensus.

39. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

40. Wednesday 8 June 2016.